Our findings support the use of naltrexone in those patients who might be less susceptible to alcohol dependence (i.e., ADH1C*1 and ALDH2*2), wherein these polymorphisms have been also related to the AUD protection [6,10,11,12,32]. The gene discussed is ADH1C; the disease is alcohol dependence.